Corcept Therapeutics Incorporated
CORT
$115.70
$1.721.51%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 31.74% | 4.89% | 11.12% | 13.75% | 18.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 31.74% | 4.89% | 11.12% | 13.75% | 18.70% |
| Cost of Revenue | 18.29% | 19.98% | -13.90% | 60.31% | 36.01% |
| Gross Profit | 31.98% | 4.66% | 11.54% | 13.00% | 18.43% |
| SG&A Expenses | 51.08% | 60.33% | 56.21% | 68.12% | 55.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.07% | 39.47% | 26.18% | 45.22% | 30.85% |
| Operating Income | 54.83% | -1,552.02% | -82.24% | -78.07% | -25.05% |
| Income Before Tax | 44.93% | -564.91% | -68.99% | -71.21% | -23.81% |
| Income Tax Expenses | 185.16% | -18.53% | -1,284.35% | -177.23% | -156.60% |
| Earnings from Continuing Operations | 22.30% | -254.58% | -21.00% | -58.34% | -0.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.30% | -254.58% | -21.00% | -58.34% | -0.96% |
| EBIT | 54.83% | -1,552.02% | -82.24% | -78.07% | -25.05% |
| EBITDA | 55.33% | -1,363.62% | -81.30% | -77.60% | -23.90% |
| EPS Basic | 20.31% | -253.31% | -21.38% | -58.60% | -2.41% |
| Normalized Basic EPS | 43.14% | -563.78% | -69.02% | -71.26% | -24.51% |
| EPS Diluted | 24.14% | -276.47% | -21.54% | -60.98% | -9.38% |
| Normalized Diluted EPS | 47.51% | -633.07% | -69.34% | -72.58% | -29.65% |
| Average Basic Shares Outstanding | 1.22% | 0.32% | 0.05% | 0.17% | 0.96% |
| Average Diluted Shares Outstanding | -1.74% | -12.84% | 1.18% | 5.03% | 8.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |